|
|
|
Subscribe
|
|
|
Contact
|
|
|
Sickle cell procedure options, data — and making a difference
Welcome to the shortest month of the year. We invite you to spend just a few of this month's minutes with the latest edition of Access Point, a newsletter exclusively for those who regularly work with the Spectra Optia® Apheresis System from Terumo Blood and Cell Technologies.
In this issue, we’re focusing on sickle cell disease (SCD) and automated red blood cell exchange (RBCX), along with ways to improve your stem cell collections from patients with SCD.
It's information to help you do what you do best: Help more patients get the best care.
But first — get a refresher on normal hemoglobin versus sickle hemoglobin with our quick guide.
|
|
|
|
|
|
|
RBCX options: Exchange, depletion, or both?
With Spectra Optia, you can choose one of three RBCX protocols, depending on an individual patient’s need and condition: Exchange, depletion, or combined depletion/exchange.
We explain the differences to help you identify the right protocol for each situation.
|
|
|
|
Case study: Data helps optimize SCD collections
Increasingly, patients with SCD are undergoing collection procedures for cell and gene therapies. But collecting stem cells from these patients poses specific challenges. To improve outcomes, Terumo Blood and Cell Technologies recently worked with Boston Children’s Hospital on a data-based approach.
|
|
|
|
Dear Access Point,
What are the differences in the types of packed red blood cell units?
— Cathi in Philadelphia, PA
Dear Cathi,
Great question! Packed red blood cells (pRBCs) are manufactured from whole blood collection. These are labeled according to the base anticoagulant (AC) in the primary collection bag, which is generally CPD or CPDA, depending on the blood bag manufacturer. Next, additive solution — either AS-1 or AS-3 — is added to extend shelf life of the pRBCs. Other pRBC units are collected via apheresis and also contain CPD/CPDA and
AS-1/AS-3. Finally, the pRBC unit can be washed to remove any excess plasma or antigens that may trigger a reaction in a patient with SCD. The table provided shows how hematocrit (Hct) varies by the type of unit. For accuracy, it is important to know the volume and Hct of each unit you are exchanging during a Spectra Optia RBCX procedure.
|
|
|
|
|
|
|
|
If you have a specific question about the Spectra Optia system, let us know. We will feature a reader question in each Access Point edition. Be sure to tell us your first name, hometown, and state or province. Questions not featured will be answered directly via email.
|
|
|
|
|
|
|
|
|
|
|
|
There's an app for that: Download a free RBCX Calcuation Tool
The app estimates the volume of replacement fluid required to perform a procedure on Spectra Optia, using the same patient data and fluid data entered on the system. It also calculates and displays estimated volume of replacement fluid required to achieve the target Hct and fraction of cells remaining. You can download the RBCX Calculation Tool from the Apple App Store or Google Play Store.
|
|
|
|
|
|
|
|
|
Award-winning program changes lives for patients with sickle cell disease in LA County
|
|
Rachel Rangwala, MD
Chief of Clinical Pathology and
Medical Director of Transfusion Medicine
Department of Pathology
Harbor-UCLA Medical Center
|
Los Angeles County has more adults with sickle cell disease (SCD) than anywhere else in California,1 making it an ideal and vital location for a treatment clinic. In 2018, Harbor-UCLA Medical Center stepped up to the challenge in a major way, and Rachel Rangwala, MD, led the establishment of a program offering outpatient automated red blood cell exchange (RBCX) transfusion therapy for patients with SCD.
Recently, the program earned a prestigious Top 10 County of Los Angeles Productivity and Quality Award, which honors programs that develop innovative ways to empower some of the county’s most vulnerable populations. Harbor’s use of RBCX for SCD resulted in better management of patients’ pain crises, reduced emergency visits and hospitalizations, and improved patient quality of life. In the process, the hospital also achieved significant Medicaid-related savings for the county.
Terumo Blood and Cell Technologies is also committed to improving therapy options for SCD, so we were excited to learn more. Rangwala, Harbor’s Chief of Clinical Pathology and Medical Director of Transfusion Medicine, generously shared her time in a recent chat to answer our questions.
|
|
|
|
|
|
Live From Lakewood
- Spectra Optia Software Version 12.1 Updates | March 14, 2024
- Manage Red Cell Spillover and Air Block on Trima Accel® | May 16, 2024
- Trima Accel Adjustments That Impact Platelet Targets | July 18, 2024
- White Blood Cell Depletion Run Values Screen and Fluid Balance Data on Spectra Optia | September 12, 2024
|
|
|
|
February 22-24, 2024, San Diego, CA
Presented by the University of California San Diego School of Medicine
|
|
|
|
April 17-19, 2024, Las Vegas, NV
Hosted by the American Society for Apheresis
|
|
|
|
|
|
You’re on the front lines of care, and we’re here to assist.
Contact us online or via 877.339.4228.
|
|
|
|
|
|
|
|
Sources:
1Jiao B, Johnson KM, Ramsey SD, Bender MA, Devine B, Basu A. Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries. Blood Adv. 2023;7(13):3276-3284.
Other sources:
Terumo Blood and Cell Technologies. Red Blood Cell Exchange (V12 RBCX) Rx Only Procedure Training (Including Single-Needle Option). 2023. Part number TS-OPTI-00799.
Lewandowski S, Howard C, Justus D, Manis J. Spectra Optia® Apheresis System collection data drives an increase in hematopoietic stem cell yield and CD34+ collection efficiency for sickle cell disease patient procedures. Abstract presented at: ASFA 2023; Minneapolis, MN.
Terumo Blood and Cell Technologies. Red Blood Cell Exchange Procedures on the Spectra Optia® Apheresis System. 2022. Part number TS-OPTI-01636.
Apple App Store is either a registered trademark or a trademark of Apple Inc. in the United States and/or other countries. Google Play Store is either a registered trademark or a trademark of Google LLC in the United States and/or other countries. CPT is either a registered trademark or a trademark of the American Medical Association in the United States and/or other countries.
|
|
|
|
|
|
©2024 Terumo BCT, Inc. | All Rights Reserved | TS-OPTI-02230 | TerumoBCT.com
|
|
|
|
|
